Core Laboratories Inc. /DE/ — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Core Laboratories reported Q3 2026 revenue of $132.1M (up 6% sequentially, down 2% year-over-year), with GAAP operating income of $12.1M and GAAP diluted EPS of $0.12. The company repurchased 87,873 shares for $1.1M and generated $1.7M free cash flow. Net debt stood at $93.4M with leverage under 1.50x. Reservoir Description revenue reached $84.3M (up 7% QoQ), while Production Enhancement posted $47.8M (up 4% QoQ). Management expects Q4 2026 revenue to remain flat sequentially with operating margins around 10%.
Why this rating
Routine quarterly earnings; revenue flat-to-down YoY; profitability weak; modest share buyback ($1.1M, <0.2% of market cap); free cash flow minimal. No major deals or restructuring.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.